Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.70
Bid: 1.60
Ask: 1.80
Change: 0.05 (3.03%)
Spread: 0.20 (12.50%)
Open: 1.65
High: 1.90
Low: 1.65
Prev. Close: 1.65
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealings and Conversion of CLNs

15 Jan 2024 07:01

RNS Number : 6148Z
IQ-AI Limited
15 January 2024
 

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Director Dealings and Conversion of Convertible Loan Notes

IQ-AI Ltd has received convertible loan note conversion notices from Trevor Brown, the CEO of IQ-AI, and Micheal Schmainda, a director of IQ-AI. Trevor Brown is converting a total of £60,000 convertible loan notes and associated interest, issued in May 2019, at a price of 1.5 pence, into 5,111,233 Ordinary Shares. Michael Schmainda is converting a total of £18,500 convertible loan notes and associated interest, issued in March 2019, at a price of 2 pence, into 1,193,681 Ordinary Shares which will be issued to his wife, Kathleen Schmainda (together the "CLN Shares").

 

Following the above transactions, Trevor Brown will hold 45,761,083 Ordinary Shares, representing approximately 23.23 per cent. of the Company's enlarged issued share capital. In addition, Kathleen Schmainda, who is also a consultant and existing shareholder in IQ-AI, will hold 10,302,081 Ordinary Shares, representing approximately 5.23 per cent. of the Company's enlarged issued share capital.

 

IQ-AI has no outstanding convertible loan notes following the above conversions. 

 

An application will be made for 6,304,914 CLN Shares to be admitted to the Official List of the UK Listing Authority by way of a Standard Listing ("Admission") and it is expected that Admission will become effective and that dealing in the CLN Shares will commence on or around 8am on 19 January 2024. The CLN Shares will rank pari passu with the existing ordinary shares of the Company.

 

Following Admission, the Company will have 196,976,456 ordinary shares of 0.01p each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company will be 196,976,456.

 

The above figure of 196,976,456 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

For further information, please contact:

 

IQ-AI Ltd

Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

About Imaging Biometrics® LLC IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website atwww.imagingbiometrics.comFollow IB on Twitter, @IQAI_IB.

 

 PDMR DEALINGS

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Trevor Brown

2

Reason for the notification

a)

Position/status

CEO

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IQ-AI Ltd

b)

LEI

213800SPW48XRJS2QH57

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of £0.01 each

 

 

 

ISIN: JE00BD4H0R42

b)

Nature of the transaction

Conversion of convertible loan notes

c)

Price(s) and volume(s)

Exercise price of each convertible loan note :1.5p

Volume: 5,111,233

d)

Aggregated information

- Aggregated volume

- Price

 

e)

Date of the transaction

15 January 2024

f)

Place of the transaction

Main Market

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Schmainda

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IQ-AI Ltd

b)

LEI

213800SPW48XRJS2QH57

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of £0.01 each

 

 

 

ISIN: JE00BD4H0R42

b)

Nature of the transaction

Conversion of convertible loan notes

c)

Price(s) and volume(s)

Exercise price of each convertible loan note :2p

Volume: 1,193,681

d)

Aggregated information

- Aggregated volume

- Price

 

e)

Date of the transaction

15 January 2024

f)

Place of the transaction

Main Market

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFFFSLLIISLIS
Date   Source Headline
1st Oct 20197:01 amRNSStoneChecker USA Market Introduction
1st Oct 20197:00 amRNSIssue of Equity
30th Sep 201911:05 amRNSSecond Price Monitoring Extn
30th Sep 201911:00 amRNSPrice Monitoring Extension
27th Sep 20197:00 amRNSFDA Clearance to Market for StoneChecker Software
16th Sep 20199:34 amRNSReplacement - Half Yearly Report to 30 June 2019
16th Sep 20197:00 amRNSHalf-year Report
4th Sep 20197:00 amRNSGrant Award
6th Aug 20197:00 amRNSCompletion of Placing and Conversion of Loan Notes
5th Aug 20192:05 pmRNSSecond Price Monitoring Extn
5th Aug 20192:00 pmRNSPrice Monitoring Extension
9th Jul 20197:00 amRNSUpdate on Gadolinium Free Imaging Project
26th Jun 20197:00 amRNSPlacing
24th Jun 20192:52 pmRNSHolding(s) in Company
20th Jun 20194:40 pmRNSSecond Price Monitoring Extn
20th Jun 20194:35 pmRNSPrice Monitoring Extension
12th Jun 20197:00 amRNSBusiness Development Agreement with CorTechs Labs
6th Jun 201911:49 amRNSResult of AGM
29th May 201911:51 amRNSIssue of Convertible Loan Notes - Correction
29th May 20198:22 amRNSIssue of Convertible Loan Notes
17th May 201912:00 pmRNSExtension of Loan Notes Redemption Date
9th May 20191:30 pmRNSNotice of AGM
9th May 201912:13 pmRNSHolding(s) in Company
30th Apr 201912:00 pmRNSPublication of Annual Report
2nd Apr 20197:00 amRNSImaging Biometrics Update
11th Mar 20197:00 amRNSIssue of Convertible Loan Notes
8th Feb 201910:29 amRNSBusiness Update
2nd Jan 201912:20 pmRNSHolding(s) in Company
13th Dec 20189:00 amRNSPrice Monitoring Extension
13th Dec 20187:00 amRNSStoneChecker 510k Update
11th Dec 20187:00 amRNSInstallation at Barrow Neurological Institute
28th Nov 20187:00 amRNSImaging Biometrics® Update
16th Nov 20187:00 amRNSFirst Commercial Sale of StoneChecker Software
22nd Oct 20187:00 amRNSIQ-AI files patent for Contrast-Free Imaging
4th Oct 20182:58 pmRNSResult of EGM and Change of Name
27th Sep 20187:00 amRNSIB announce agreement to develop a diagnostic tool
18th Sep 20187:00 amRNSProposed name change and notice of EGM
11th Sep 20189:00 amRNSDirector/PDMR Shareholding
11th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Sep 20187:00 amRNSHalf-year Report
6th Aug 20182:51 pmRNSHolding(s) in Company
6th Aug 20187:00 amRNSAppointment of CEO to the Operating Subsidiaries
1st Aug 20184:28 pmRNSPublication of a Prospectus
31st Jul 20183:54 pmRNSResult of AGM and GM
18th Jul 20181:24 pmRNSNon Regulatory - Vox Markets Podcast
18th Jul 20188:57 amRNSHolding(s) in Company
17th Jul 20187:00 amRNSECOG-ACRIN TO PROCESS CLINICAL TRIAL DATA USING IB
16th Jul 20187:00 amRNSPlacing, Notice of AGM and GM
2nd Jul 20188:34 amRNSMedimsight and IB Enter into Partnership
13th Jun 20187:00 amRNSImaging Biometrics and QMENTA announce partnership

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.